VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 201 filers reported holding VAXCYTE INC in Q3 2023. The put-call ratio across all filers is 0.83 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $660 | +40.1% | 12,966 | +38.4% | 0.00% | +100.0% |
| Q2 2023 | $471 | +371.0% | 9,370 | +252.5% | 0.00% | – |
| Q1 2023 | $100 | -21.9% | 2,658 | 0.0% | 0.00% | – |
| Q4 2022 | $128 | -99.7% | 2,658 | +46.9% | 0.00% | – |
| Q3 2022 | $43,000 | +10.3% | 1,810 | 0.0% | 0.00% | – |
| Q2 2022 | $39,000 | +44.4% | 1,810 | +69.3% | 0.00% | – |
| Q1 2022 | $27,000 | +8.0% | 1,069 | 0.0% | 0.00% | – |
| Q4 2021 | $25,000 | -7.4% | 1,069 | 0.0% | 0.00% | – |
| Q3 2021 | $27,000 | +12.5% | 1,069 | 0.0% | 0.00% | – |
| Q2 2021 | $24,000 | +14.3% | 1,069 | 0.0% | 0.00% | – |
| Q1 2021 | $21,000 | -25.0% | 1,069 | 0.0% | 0.00% | – |
| Q4 2020 | $28,000 | – | 1,069 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $90,711,000 | 29.04% |
| Medicxi Ventures Management (Jersey) Ltd | 3,774,956 | $82,142,000 | 17.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 832,166 | $18,108,000 | 9.12% |
| GREAT POINT PARTNERS LLC | 985,153 | $21,437,000 | 5.14% |
| Kynam Capital Management, LP | 723,781 | $15,749,000 | 4.02% |
| Ghost Tree Capital, LLC | 325,000 | $7,072,000 | 3.68% |
| Frazier Life Sciences Management, L.P. | 1,787,405 | $38,894,000 | 3.67% |
| RA Capital Management | 4,581,203 | $99,687,000 | 2.66% |
| Opaleye Management Inc. | 190,000 | $4,134,000 | 1.86% |
| Soleus Capital Management, L.P. | 370,650 | $8,065,000 | 1.26% |